SSGA Active Trust has released its latest financial report for the State Street My2030 High Yield Corporate Bond ETF, providing insight into its asset management activities. The report, filed on October 28, 2026, highlights a total asset value of approximately $6.34 million, with net assets reported at around $6.26 million.
This filing is significant for SSGA Active Trust as it reflects the fund's current financial health and investment strategy, which may attract potential investors. In a time when the investment management sector is under increased scrutiny, transparency in reporting is crucial for maintaining investor confidence.
Background
SSGA Active Trust, identified under Central Index Key (CIK) 0001516212, operates in the investment management sector. The company focuses on managing various funds, including the State Street My2030 High Yield Corporate Bond ETF. The recent filing is part of a series of reports submitted on the same date, indicating ongoing compliance with regulatory requirements.
What the Filing Says
The NPORT-P filing reveals that as of August 31, 2026, SSGA Active Trust's My2030 ETF held total assets of $6,336,376.96, with total liabilities of $74,406.26, resulting in net assets of $6,261,970.70. The report includes details on the fund's investment strategy, which focuses on high-yield corporate bonds.
"The fund's monthly total returns have shown fluctuations, indicating the dynamic nature of the current market environment," the filing noted.
Impact
This filing may influence a variety of stakeholders, including current and potential investors, financial analysts, and competitors in the investment management industry. The disclosure of detailed financial metrics can help investors make informed decisions about their portfolios. Additionally, competitors may analyze SSGA's strategies and performance metrics to adjust their own offerings.
What's Next
The filing does not specify what happens next for SSGA Active Trust or its My2030 ETF. However, continued monitoring of the fund's performance and additional filings will likely follow as the company seeks to maintain transparency with its investors.
Read Next
van Houte Hans Reports Stock Transactions at Nurix Therapeutics
Hansen Gwenn Acquires and Sells Shares at Nurix Therapeutics
Drouillard Vincent Amends Filing to Correct Share Sale Details
Drouillard Vincent reports sale of 10,000 shares in AerCap
Gilead Sciences CEO Daniel O'Day Executes Multiple Stock Sales
Le Peuch Olivier Sells 25,000 Shares of SLB Limited





